Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
NCT06029933
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24, 2024/25, and 2026/27 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Influenza
- Community-acquired Pneumonia
- Cardiovascular Events
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Kaiser Permanente
- Last updated on ClinicalTrials.gov
- August 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Kaiser Permanente Northern California (entire region) · Oakland, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.